Production Method Affects the Pharmacokinetic and Ex Vivo Biological Properties of Low Molecular Weight Heparins

Summary

Low molecular weight (LMW) heparins have prolonged circulating half-lives relative to unfractionated heparin, but the rates of plasma clearance differ between different LMW preparations. To determine the impact of method of production on their pharmacokinetic and ex vivo biological properties, two LMW heparins of similar molecular weight distribution, Logiparin and Fragmin, were radiolabelled with ¹²⁵I, administered intravenously with 4 mg/kg of carrier drug into rabbits, and the circulating radiolabelled material and anti-Xa activity were analysed by size exclusion chromatography and affinity for antithrom#bin and Polybrene. Following administration of Logiparin, the anti-Xa amidolytic activity was eliminated with the same half-life as the anti#thrombin-binding radiolabel and was not neutralised by antibody against tissue factor pathway inhibitor (TFPI). Larger molecules were cleared preferentially and were no longer detectable 8 h post injection. These findings resemble those we have previously described for Enoxaparin. After Fragmin administration the antithrombin binding radiolabel was cleared more rapidly than the anti-Xa activity, and at late times after injection a significant amount of this activity was neutralised by antibody against TFPI. Sulphated radiolabel was eliminated with a similar half-life to the anti-Xa activity and sulphated molecules >6000 Da remained in the circulation 8 h after administra#tion. Fragmin, unlike Logiparin and Enoxaparin, has no negatively charged sulphamino group at the reducing end of the molecule. We sug#gest that this minimises cellular interaction and protects the larger molecules from elimination. They remain in the circulation, contributing to anti-Xa activity by binding TFPI. Thus the method of production of LMW heparins may significantly influence their pharmacokinetic properties and circulating anticoagulant activities.

• References

• 1 Dawes J, Pepper D. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
• 2 Boneu B, Caranobe C, Sié P, Houin G. Pharmacokinetics of heparin and related polysaccharides. Ann NY Acad Sci 1989; 556: 282-291
• 3 Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. John Wiley and Sons; Chichester, New York, Brisbane, Toronto, Singapore: 1992
• 4 Doutrempuich C, Guyot M, Lalanne M, Deharo E, Walenga J, Fareed J. Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects. Thromb Res 1989; 55: 419-426
• 5 Brieger D, Dawes J. Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane). Thromb Haemost 1994; 72: 275-280
• 6 Lam L, Silbert J, Rosenberg R. The separation of active and inactive forms of heparin. Biochem Biophys Res Comm 1976; 69: 570-577
• 7 Dawes J, Prowse C, Pepper D. The measurement of heparin and other therapeutic sulphated polysaccharides in plasma serum and urine. Thromb Haemost 1985; 54: 630-634
• 8 Greenwood F, Hunter W, Glover J. The preparation of ¹³¹I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 14: 114-123
• 9 Andersson L, Barrowcliffe T, Holmer E, Johnson E, Sims G. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 09: 575-583
• 10 Hodson B, Pepper D, Dawes J. Novel affinity chromatographic system for the single step purification of glycosaminoglycans from complex systems using volatile buffers. J Chromatog 1991; 565: 416-423
• 11 Teien A, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 12 Fareed J, Walenga J, Hoppensteadt D, Huan X, Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann NY Acad Sci 1989; 556: 333-353
• 13 Østergaard P, Nilsson B, Bergquist D, Hedner U, Pedersen P. The effect of low molecular weight heparin on experimental thrombosis and haemostasis – the influence of production metho. Thromb Res 1987; 45: 739-749
• 14 Mardiguian J. French Patent No. 2482603 1981
• 15 Neilsen J, Østergaard P. Chemistry of heparin and low molecular weight heparin. Acta Chir Scand Suppl 1988; 543: 52-56
• 16 Cifonelli J, King J. The distribution of 2-acetaminido-2-deoxy-D-glucose residues in mammalian heparins. Carb Res 1972; 21: 173-186
• 17 Bara L, Billaud B, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-636
• 18 Bratt G, Tomebohm E, Lockner D. Low molecular weight heparin (KABI 2165, FRAGMIN): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-619
• 19 Matzsch T, Bergqvist D, Hedner U, Øtsergaard P. Effects of an enzymati#cally depolymerised heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987; 57: 097-101
• 20 Lindahl A, Sandset P, Abildgaard U. The present status of tissue factor pathway inhibitor. Blood Coag Fibrinol 1992; 03: 439-449
• 21 Bregengaard C, Nordfang O, Østergaard P, Petersen J, Meyn G, Diness V, Svendsen O, Hedner U. Pharmacokinetics of full length and two domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-457
• 22 Lamkjoer A, Østergaard P, Flodgaard H. Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro. Thromb Res 1994; 75: 185-194
• 23 van RijnJ, Trillou M, Mardiguian J, Tobelem G, Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res 1987; 45: 211-222
• 24 Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58: 932-935
• 25 Sandset P, Abildgaard U, Larsen M. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 801-813
• 26 Valentin S, Larnkjor A, Østergaard P, Nielsen J, Nordfang O. Characterisation of the binding between tissue factor pathway inhibitor and glycosaminoglycans. Thromb Res 1994; 75: 173-183
• 27 Wam-Cramer BJ, Maki SL, Rapaport SI. Heparin-releasable and platelet pools of tissue factor pathway inhibitor in rabbits. Thromb Haemost 1993; 69: 221-226